Pyrophosphoric Acid

Pyrophosphoric Acid

SCHEMBL184653

O=P([O-])([O-])OP(=O)([O-])[O-].[Ca+2].[Na+].[Na+]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Pyrophosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
CA1 P00915 2/20 0.35
CA4 P22748 2/20 0.35
CA5A P35218 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
SLC34A1 Q06495 1/20 0.33
FDPS P14324 1/20 0.31
BLM P54132 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
BTN3A1 O00481 1/20 0.30
KDM4E B2RXH2 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrophosphoric Acid SCHEMBL5550827 1.00 LMNA (0.35) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL4418857 1.00 LMNA (0.35) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL18670526 1.00 LMNA (0.35) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL59778 1.00 LMNA (0.35) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL11646886 0.96 CA1 (0.33) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL5884527 0.96 CA1 (0.33) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL7106242 0.96 CA1 (0.33) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL11779407 0.96 CA1 (0.33) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL9422113 0.96 CA1 (0.33) LMNACA1CA4CA5ACA5B
Pyrophosphoric Acid SCHEMBL452253 0.96 CA1 (0.33) LMNACA1CA4CA5ACA5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119943952-A Positive electrode material, positive electrode plate, battery cell, sodium ion battery and electricity utilization device 宁德时代新能源科技股份有限公司 2025-05-06 CN claimed
US-12193868-B2 Breast calcification imaging phantoms and methods of use THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2025-01-14 US claimed
EP-2934694-B1 ANTI-PLAQUE ORAL COMPOSITIONS BHUSHAN RAJIV (US) 2023-06-28 EP claimed
US-20220401057-A1 Breast Calcification Imaging Phantoms and Methods of Use THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2022-12-22 US claimed
US-10702463-B2 Oral compositions for anticavity and desensitization use THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-07-07 US claimed
EP-2432444-B1 ORAL COMPOSITIONS CONTAINING POLYGUANIDINIUM COMPOUNDS AND METHODS OF MANUFACTURE AND USE THEREOF COLGATE PALMOLIVE CO (US) 2017-08-23 EP claimed
US-20160279042-A1 Dental Anti-Hypersensitivity Composition and Method THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2016-09-29 US claimed
US-20150335557-A1 ANTI-PLAQUE ORAL COMPOSITIONS BHUSNAN RAJIV (US) 2015-11-26 US claimed
EP-2934694-A1 ANTI-PLAQUE ORAL COMPOSITIONS Bhushan, Rajiv (US) 2015-10-28 EP claimed
WO-2014100775-A1 ANTI-PLAQUE ORAL COMPOSITIONS BHUSHAN RAJIV (US) 2014-06-26 WO claimed
US-6524558-B2 For calcifying dental tissue, e.g., preventing or treating dental hypersensitivity THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK 2003-02-25 US claimed
US-20030017209-A1 Breath protection microcapsules WARNER-LAMBERT COMPANY 2003-01-23 US claimed
US-6436370-B1 ORAL COMPOSITION OF ARGININE BICARBONATE AND CALCIUM CARBONATE PROMOTES THE FORMATION OF DENTINAL TUBULE PLUGS AIDED BY COMBINING CALCIUM AND PHOSPHATE IN THE FLUID THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2002-08-20 US claimed
US-20020068039-A1 Oral care compositions containing grapefruit seed extract PAN PAULINE C (US) 2002-06-06 US claimed
US-20020064504-A1 Dental anti-hypersensitivity composition and method THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2002-05-30 US claimed
US-6375459-B1 Apparatus and method for cleaning teeth DEKA PRODUCTS LIMITED PARTNERSHIP 2002-04-23 US claimed
EP-1187593-A1 DENTAL ANTI-HYPERSENSITIVITY COMPOSITION AND METHOD The Research Foundation of State University of New York (US) 2002-03-20 EP claimed
WO-2002011641-A2 APPARATUS AND METHOD FOR CLEANING TEETH DEKA PRODUCTS LIMITED PARTNERSHIP (US) 2002-02-14 WO claimed
WO-2000078270-A1 DENTAL ANTI-HYPERSENSITIVITY COMPOSITION AND METHOD THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2000-12-28 WO claimed
US-3985675-A PARTIALLY DEHYDRATED AMORPHOUS CALCIUM SODIUM PYROPHOSPHATE MONSANTO COMPANY (US) 1976-10-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030017209-A1 Breath protection microcapsules MLYCD, SCD5, FBP1 LMNA 3674/4885CA1 3185/4885CA4 1720/4885
US-20150335557-A1 ANTI-PLAQUE ORAL COMPOSITIONS MGMT, CAPG, TRPM7 LMNA 3929/4885CA1 2685/4885CA4 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.